Skip to main content
Premium Trial:

Request an Annual Quote

Xceleron and Servier to Accelerate Drug Development Using Microdosing

NEW YORK, Dec. 8, (GenomeWeb News) - Under a collaborative agreement, XCeleron will provide Servier accelerator mass spectrometry services to study candidate drugs in humans, Xceleron said yesterday.


Servier will accelerate drug development by testing candidate drugs in phase 0 microdose studies instead of waiting for conventional phase 1 studies.


The 12-month rolling agreement allows the pharmaceutical company to include early human studies as part of its drug candidate selection process, Xceleron said.


Financial details were not disclosed.

The Scan

Science Confidence Boost

The New York Times reports that a new poll finds trust in science and scientists has increased with the COVID-19 pandemic.

Appeal and Funds

Some grant applications denied funding due to an Australian Research Council rule change have now been funded following an appeal, the Guardian reports.

Surveillance for Variants

Vox writes that the detection of the Omicron SARS-CoV-2 variant highlights the need for improved viral genomic surveillance.

Nature Papers Examine Taxonomic Gaps in Plant Sequencing, SARS-CoV-2-Human Interactome

In Nature this week: plant genome sequencing dominated by affluent countries, and more.